Cargando…

Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a major nonacquired immune deficiency syndrome-defining condition for persons with human immunodeficiency virus (PWH). We aimed to validate noninvasive tests for the diagnosis of NAFLD in PWH. METHODS: This is a cross-sectional study of PWH on...

Descripción completa

Detalles Bibliográficos
Autores principales: Busca, C, Sánchez-Conde, M, Rico, M, Rosas, M, Valencia, E, Moreno, A, Moreno, V, Martín-Carbonero, L, Moreno, S, Pérez-Valero, I, Bernardino, J I, Arribas, J R, González, J, Olveira, A, Castillo, P, Abadía, M, Guerra, L, Mendez, C, Montes, M L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297309/
https://www.ncbi.nlm.nih.gov/pubmed/35873289
http://dx.doi.org/10.1093/ofid/ofac279
_version_ 1784750449219338240
author Busca, C
Sánchez-Conde, M
Rico, M
Rosas, M
Valencia, E
Moreno, A
Moreno, V
Martín-Carbonero, L
Moreno, S
Pérez-Valero, I
Bernardino, J I
Arribas, J R
González, J
Olveira, A
Castillo, P
Abadía, M
Guerra, L
Mendez, C
Montes, M L
author_facet Busca, C
Sánchez-Conde, M
Rico, M
Rosas, M
Valencia, E
Moreno, A
Moreno, V
Martín-Carbonero, L
Moreno, S
Pérez-Valero, I
Bernardino, J I
Arribas, J R
González, J
Olveira, A
Castillo, P
Abadía, M
Guerra, L
Mendez, C
Montes, M L
author_sort Busca, C
collection PubMed
description BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a major nonacquired immune deficiency syndrome-defining condition for persons with human immunodeficiency virus (PWH). We aimed to validate noninvasive tests for the diagnosis of NAFLD in PWH. METHODS: This is a cross-sectional study of PWH on stable antiretroviral therapy with persistently elevated transaminases and no known liver disease. The area under the receiver operating characteristic curve (AUROC) was calculated to compare the diagnostic accuracy of liver biopsy with abdominal ultrasound, transient elastography (TE) (including controlled attenuation parameter [CAP]), and noninvasive markers of steatosis (triglyceride and glucose index [TyG], hepatic steatosis index [HSI], fatty liver index [FLI]) and fibrosis ([FIB]-4, aminotransferase-to-platelet ratio index [APRI], NAFLD fibrosis score). We developed a diagnostic algorithm with serial combinations of markers. RESULTS: Of 146 patients with increased transaminase levels, 69 underwent liver biopsy (90% steatosis, 61% steatohepatitis, and 4% F ≥3). The AUROC for steatosis was as follows: ultrasound, 0.90 (0.75–1); CAP, 0.94 (0.88–1); FLI, 0.81 (0.58–1); HSI, 0.74 (0.62–0.87); and TyG, 0.75 (0.49–1). For liver fibrosis ≥F3, the AUROC for TE, APRI, FIB-4, and NAFLD fibrosis score was 0.92 (0.82–1), 0.96 (0.90–1), 0.97 (0.93–1), and 0.85 (0.68–1). Optimal diagnostic performance for liver steatosis was for 2 noninvasive combined models of tests with TyG and FLI/HSI as the first tests and ultrasound or CAP as the second tests: AUROC = 0.99 (0.97–1, P < .001) and 0.92 (0.77–1, P < .001). CONCLUSIONS: Ultrasound and CAP performed best in diagnosing liver steatosis, and FLI, TyG, and HSI performed well. We propose an easy-to-implement algorithm with TyG or FLI as the first test and ultrasound or CAP as the second test to accurately diagnose or exclude NAFLD.
format Online
Article
Text
id pubmed-9297309
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92973092022-07-21 Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens Busca, C Sánchez-Conde, M Rico, M Rosas, M Valencia, E Moreno, A Moreno, V Martín-Carbonero, L Moreno, S Pérez-Valero, I Bernardino, J I Arribas, J R González, J Olveira, A Castillo, P Abadía, M Guerra, L Mendez, C Montes, M L Open Forum Infect Dis Major Article BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a major nonacquired immune deficiency syndrome-defining condition for persons with human immunodeficiency virus (PWH). We aimed to validate noninvasive tests for the diagnosis of NAFLD in PWH. METHODS: This is a cross-sectional study of PWH on stable antiretroviral therapy with persistently elevated transaminases and no known liver disease. The area under the receiver operating characteristic curve (AUROC) was calculated to compare the diagnostic accuracy of liver biopsy with abdominal ultrasound, transient elastography (TE) (including controlled attenuation parameter [CAP]), and noninvasive markers of steatosis (triglyceride and glucose index [TyG], hepatic steatosis index [HSI], fatty liver index [FLI]) and fibrosis ([FIB]-4, aminotransferase-to-platelet ratio index [APRI], NAFLD fibrosis score). We developed a diagnostic algorithm with serial combinations of markers. RESULTS: Of 146 patients with increased transaminase levels, 69 underwent liver biopsy (90% steatosis, 61% steatohepatitis, and 4% F ≥3). The AUROC for steatosis was as follows: ultrasound, 0.90 (0.75–1); CAP, 0.94 (0.88–1); FLI, 0.81 (0.58–1); HSI, 0.74 (0.62–0.87); and TyG, 0.75 (0.49–1). For liver fibrosis ≥F3, the AUROC for TE, APRI, FIB-4, and NAFLD fibrosis score was 0.92 (0.82–1), 0.96 (0.90–1), 0.97 (0.93–1), and 0.85 (0.68–1). Optimal diagnostic performance for liver steatosis was for 2 noninvasive combined models of tests with TyG and FLI/HSI as the first tests and ultrasound or CAP as the second tests: AUROC = 0.99 (0.97–1, P < .001) and 0.92 (0.77–1, P < .001). CONCLUSIONS: Ultrasound and CAP performed best in diagnosing liver steatosis, and FLI, TyG, and HSI performed well. We propose an easy-to-implement algorithm with TyG or FLI as the first test and ultrasound or CAP as the second test to accurately diagnose or exclude NAFLD. Oxford University Press 2022-06-09 /pmc/articles/PMC9297309/ /pubmed/35873289 http://dx.doi.org/10.1093/ofid/ofac279 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Busca, C
Sánchez-Conde, M
Rico, M
Rosas, M
Valencia, E
Moreno, A
Moreno, V
Martín-Carbonero, L
Moreno, S
Pérez-Valero, I
Bernardino, J I
Arribas, J R
González, J
Olveira, A
Castillo, P
Abadía, M
Guerra, L
Mendez, C
Montes, M L
Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens
title Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens
title_full Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens
title_fullStr Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens
title_full_unstemmed Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens
title_short Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens
title_sort assessment of noninvasive markers of steatosis and liver fibrosis in human immunodeficiency virus-monoinfected patients on stable antiretroviral regimens
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297309/
https://www.ncbi.nlm.nih.gov/pubmed/35873289
http://dx.doi.org/10.1093/ofid/ofac279
work_keys_str_mv AT buscac assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT sanchezcondem assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT ricom assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT rosasm assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT valenciae assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT morenoa assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT morenov assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT martincarbonerol assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT morenos assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT perezvaleroi assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT bernardinoji assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT arribasjr assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT gonzalezj assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT olveiraa assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT castillop assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT abadiam assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT guerral assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT mendezc assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens
AT montesml assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens